Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Gain Therapeutics (GANX – Research Report). The associated price target remains the same with $5.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Jason McCarthy has given his Buy rating due to a combination of factors related to Gain Therapeutics’ promising developments in their Parkinson’s disease program. The company’s focus on the Phase 1b trial of GT-02287, which is a key proof of concept study, is progressing well. Interim data expected in mid-2025 is anticipated to provide significant insights into the drug’s efficacy in Parkinson’s patients, potentially confirming the positive results seen in healthy subjects.
Furthermore, GT-02287 has shown encouraging preclinical results, including the restoration of GCase function and reduction of toxic lipid substrates in animal models. These findings, coupled with the company’s solid financial position, which should support operations through the release of interim data, contribute to McCarthy’s optimistic outlook. The potential for GT-02287 to become a groundbreaking treatment for Parkinson’s disease underpins the Buy rating, as it could significantly impact the company’s valuation if successful.
In another report released today, Scotiabank also maintained a Buy rating on the stock with a $12.00 price target.
GANX’s price has also changed slightly for the past six months – from $1.745 to $1.860, which is a 6.59% increase.